DEAN WHITLEY: Open Payments
NPI 1093721037 · MADISON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,813 in 69 payments from 19 companies in 2025. Trend: 2023 $2,044 · 2024 $1,777 · 2025 $1,813
Food & beverage: $1,813
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $295 |
| E.R. Squibb & Sons, L.L.C. | 6 | $217 |
| Alnylam Pharmaceuticals Inc. | 7 | $202 |
| Novartis Pharmaceuticals Corporation | 10 | $177 |
| Boston Scientific Corporation | 3 | $168 |
| Merck Sharp & Dohme LLC | 5 | $115 |
| Novo Nordisk Inc | 4 | $88 |
| ABIOMED | 3 | $74 |
| BridgeBio Pharma, Inc. | 3 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $67 |
Products named: WAINUA, AMVUTTRA, CAMZYOS, LEQVIO, WATCHMAN Access System, VERQUVO, ELIQUIS, Wegovy.
Industry payments across MS — which companies pay providers there.
